Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference
January 02 2019 - 4:15PM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, announced today that CEO Stéphane Bancel will
present an update on the Company and its pipeline of mRNA
development programs at this year’s 37th annual J.P. Morgan
Healthcare Conference.
Mr. Bancel’s presentation will take place on Tuesday, January 8,
2019 at 10:30 a.m. PT in the Colonial Room at The Westin St.
Francis Hotel in San Francisco. The presentation will be followed
by a question and answer session. A live webcast of both the
presentation and question and answer session can be accessed
on the investors section of Moderna’s website at
investors.modernatx.com. A replay of the webcast also will be
archived on Moderna’s website for up to 30 days following the
presentation.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca and
Merck & Co., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense; the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been ranked in the top ten of Science’s
list of top biopharma industry employers for the past four
years. To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190102005536/en/
Media:Jason GlashowHead of Corporate
Communications617-674-5648jason.glashow@modernatx.com
Investors:Lorence KimChief Financial
Officer617-209-5849lorence.kim@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024